Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer

被引:27
作者
He, Chaobin [1 ]
Huang, Xin [1 ]
Zhang, Yu [2 ]
Cai, Zhiyuan [1 ]
Lin, Xiaojun [1 ]
Li, Shengping [1 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Pancreatobiliary Surg, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China
关键词
locally advanced pancreatic cancer; irreversible electroporation; chemotherapy; efficacy; SEER; INDUCTION CHEMOTHERAPY; GEMCITABINE; CHEMORADIOTHERAPY; ADENOCARCINOMA; RADIOTHERAPY; CARCINOMA; RESECTION; ABLATION; THERAPY; BENEFIT;
D O I
10.3389/fonc.2020.00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Locally advanced pancreatic cancer (LAPC) has a dismal prognosis even after standard chemotherapy, and local progression contributes to nearly one-third of the deaths of these patients. As a local destructive method, irreversible electroporation (IRE) can feasibly treat LAPC. The aim of this study was to evaluate IRE combined with chemotherapy as a new treatment and compare its efficacy with that of chemotherapy alone in patients with LAPC. The data of LAPC patients who received chemotherapy with or without IRE were extracted from Surveillance, Epidemiology, and End Results (SEER) database and medical records of Sun Yat-sen University Cancer Center (SYSUCC). The efficacy of these two treatments was compared using propensity score matching (PSM) analysis. LAPC patients treated with the combination therapy had better overall survival (OS). Significantly higher cancer-specific survival (CSS) and progression-free survival (PFS) rates were also observed in patients after IRE combined with chemotherapy, compared with chemotherapy alone. IRE combined with chemotherapy was established as a favorable factor for OS, CSS, and PFS in LAPC patients. This combination method may be a more suitable treatment for patients with LAPC.
引用
收藏
页数:12
相关论文
共 32 条
[1]   Stage III pancreatic cancer and the role of irreversible electroporation [J].
Al Efishat, Mohammad ;
Wolfgang, Christopher L. ;
Weiss, Matthew J. .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
[2]   Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies [J].
Austin, Peter C. .
PHARMACEUTICAL STATISTICS, 2011, 10 (02) :150-161
[3]   Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer [J].
Belfiore, Giuseppe ;
Belfiore, Maria Paola ;
Reginelli, Alfonso ;
Capasso, Raffaella ;
Romano, Francesco ;
Ianniello, Giovanni Pietro ;
Cappabianca, Salvatore ;
Brunese, Luca .
MEDICAL ONCOLOGY, 2017, 34 (03)
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[6]   Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].
Callery, Mark P. ;
Chang, Kenneth J. ;
Fishman, Elliot K. ;
Talamonti, Mark S. ;
Traverso, L. William ;
Linehan, David C. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733
[7]   Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? [J].
Carino, Nicola de Liguori ;
O'Reilly, Derek A. ;
Siriwardena, Ajith K. ;
Valle, Juan W. ;
Radhakrishna, Ganesh ;
Pihlak, Rille ;
McNamara, Mairead G. .
EJSO, 2018, 44 (10) :1486-1493
[8]   A POWER PRIMER [J].
COHEN, J .
PSYCHOLOGICAL BULLETIN, 1992, 112 (01) :155-159
[9]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[10]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509